Emdocam

国家: 欧盟

语言: 英文

来源: EMA (European Medicines Agency)

现在购买

资料单张 资料单张 (PIL)
16-06-2021
产品特点 产品特点 (SPC)
16-06-2021
公众评估报告 公众评估报告 (PAR)
18-11-2021

有效成分:

meloxicam

可用日期:

Emdoka bvba

ATC代码:

QM01AC06

INN(国际名称):

meloxicam

治疗组:

Horses; Pigs; Cattle

治疗领域:

Oxicams

疗效迹象:

CattleFor use in acute respiratory infection with appropriate antibiotic therapy to reduce clinical signs. For use in diarrhoea in combination with oral rehydration therapy to reduce clinical signs in calves of over one week of age and young, non-lactating cattle. For adjunctive therapy in the treatment of acute mastitis, in combination with antibiotic therapy.PigsFor use in noninfectious locomotor disorders to reduce the symptoms of lameness and inflammation. For adjunctive therapy in the treatment of puerperal septicaemia and toxaemia (mastitits-metritis-agalactia syndrome) with appropriate antibiotic therapy.HorsesFor use in the alleviation of inflammation and relief of pain in both acute and chronic musculoskeletal disorders. For the relief of pain associated with equine colic.Dogs: Alleviation of inflammation and pain in both acute and chronic musculo-skeletal disorders. Reduction of post-operative pain and inflammation following orthopaedic and soft tissue surgery.Cats:Reduction of post-operative pain after ovariohysterectomy and minor soft tissue surgery.

產品總結:

Revision: 9

授权状态:

Authorised

授权日期:

2011-08-18

资料单张

                                41
B. PACKAGE LEAFLET
42
PACKAGE LEAFLET:
EMDOCAM 20 MG/ML SOLUTION FOR INJECTION FOR CATTLE, PIGS AND HORSES
1.
NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER AND OF
THE MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH
RELEASE, IF DIFFERENT
Marketing authorisation holder
Emdoka bvba
J. Lijsenstraat 16
B-2321 Hoogstraten
Belgium
Manufacturer responsible for batch release:
Produlab Pharma bv
NL-4941 SJ Raamsdonksveer
The Netherlands
2.
NAME OF THE VETERINARY MEDICINAL PRODUCT
Emdocam 20 mg/ml solution for injection for cattle, pigs and horses
meloxicam
3.
STATEMENT OF THE ACTIVE SUBSTANCE(S) AND OTHER INGREDIENTS
One ml contains:
ACTIVE SUBSTANCE:
Meloxicam
20 mg
EXCIPIENT:
Ethanol (96%)
150 mg
Clear yellow solution for injection.
4.
INDICATION(S)
Cattle
For use in acute respiratory infection with appropriate antibiotic
therapy to reduce clinical signs in cattle.
For use in diarrhoea in combination with oral re-hydration therapy to
reduce clinical signs in calves of
over one week of age and young, non-lactating cattle.
For adjunctive therapy in the treatment of acute mastitis, in
combination with antibiotic therapy.
For the relief of post-operative pain following dehorning in calves.
Pigs
For use in non-infectious locomotor disorders to reduce the symptoms
of lameness and inflammation.
For adjunctive therapy in the treatment of puerperal septicaemia and
toxaemia (mastitis-metritis-agalactia
syndrome) with appropriate antibiotic therapy.
Horses
43
For use in the alleviation of inflammation and relief of pain in both
acute and chronic musculo-skeletal
disorders.
For the relief of pain associated with equine colic.
5.
CONTRAINDICATIONS
Do not use in horses less than 6 weeks of age.
Do not use in pregnant or lactating mares.
Do not use in animals suffering from impaired hepatic, cardiac or
renal function and haemorrhagic
disorders, or where there is evidence of ulcerogenic gastrointestinal
lesions.
Do not use in case of hypersensitivity to the active substance or to
any of the excipients.
For the treat
                                
                                阅读完整的文件
                                
                            

产品特点

                                1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE VETERINARY MEDICINAL PRODUCT
Emdocam 20 mg/ml solution for injection for cattle, pigs and horses
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
One ml contains:
ACTIVE SUBSTANCE:
Meloxicam
20 mg
EXCIPIENT:
Ethanol
150 mg
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Solution for injection.
Clear yellow solution.
4.
CLINICAL PARTICULARS
4.1
TARGET SPECIES
Cattle, pigs and horses.
4.2
INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
Cattle
For use in acute respiratory infection with appropriate antibiotic
therapy to reduce clinical signs in cattle.
For use in diarrhoea in combination with oral re-hydration therapy to
reduce clinical signs in calves of
over one week of age and young, non-lactating cattle.
For adjunctive therapy in the treatment of acute mastitis, in
combination with antibiotic therapy.
For the relief of post-operative pain following dehorning in calves.
Pigs
For use in non-infectious locomotor disorders to reduce the symptoms
of lameness and inflammation.
For adjunctive therapy in the treatment of puerperal septicaemia and
toxaemia (mastitis-metritis-agalactia
syndrome) with appropriate antibiotic therapy.
Horses
For use in the alleviation of inflammation and relief of pain in both
acute and chronic musculo-skeletal
disorders.
For the relief of pain associated with equine colic.
4.3
CONTRAINDICATIONS
See also section 4.7.
Do not use in horses less than 6 weeks of age.
Do not use in animals suffering from impaired hepatic, cardiac or
renal function and haemorrhagic
disorders, or where there is evidence of ulcerogenic gastrointestinal
lesions.
3
Do not use in case of hypersensitivity to the active substance or to
any of the excipients.
For the treatment of diarrhoea in cattle, do not use in animals of
less than one week of age.
4.4
SPECIAL WARNINGS FOR EACH TARGET SPECIES
Treatment of calves with Emdocam 20 minutes before dehorning reduces
post-operative pain. Emdocam
alone will not provide adequate pain relief dur
                                
                                阅读完整的文件
                                
                            

其他语言的文件

资料单张 资料单张 保加利亚文 16-06-2021
产品特点 产品特点 保加利亚文 16-06-2021
公众评估报告 公众评估报告 保加利亚文 18-11-2021
资料单张 资料单张 西班牙文 16-06-2021
产品特点 产品特点 西班牙文 16-06-2021
公众评估报告 公众评估报告 西班牙文 18-11-2021
资料单张 资料单张 捷克文 16-06-2021
产品特点 产品特点 捷克文 16-06-2021
公众评估报告 公众评估报告 捷克文 18-11-2021
资料单张 资料单张 丹麦文 16-06-2021
产品特点 产品特点 丹麦文 16-06-2021
公众评估报告 公众评估报告 丹麦文 18-11-2021
资料单张 资料单张 德文 16-06-2021
产品特点 产品特点 德文 16-06-2021
公众评估报告 公众评估报告 德文 18-11-2021
资料单张 资料单张 爱沙尼亚文 16-06-2021
产品特点 产品特点 爱沙尼亚文 16-06-2021
公众评估报告 公众评估报告 爱沙尼亚文 18-11-2021
资料单张 资料单张 希腊文 16-06-2021
产品特点 产品特点 希腊文 16-06-2021
公众评估报告 公众评估报告 希腊文 18-11-2021
资料单张 资料单张 法文 16-06-2021
产品特点 产品特点 法文 16-06-2021
公众评估报告 公众评估报告 法文 18-11-2021
资料单张 资料单张 意大利文 16-06-2021
产品特点 产品特点 意大利文 16-06-2021
公众评估报告 公众评估报告 意大利文 18-11-2021
资料单张 资料单张 拉脱维亚文 16-06-2021
产品特点 产品特点 拉脱维亚文 16-06-2021
公众评估报告 公众评估报告 拉脱维亚文 18-11-2021
资料单张 资料单张 立陶宛文 16-06-2021
产品特点 产品特点 立陶宛文 16-06-2021
公众评估报告 公众评估报告 立陶宛文 18-11-2021
资料单张 资料单张 匈牙利文 16-06-2021
产品特点 产品特点 匈牙利文 16-06-2021
公众评估报告 公众评估报告 匈牙利文 18-11-2021
资料单张 资料单张 马耳他文 16-06-2021
产品特点 产品特点 马耳他文 16-06-2021
公众评估报告 公众评估报告 马耳他文 18-11-2021
资料单张 资料单张 荷兰文 16-06-2021
产品特点 产品特点 荷兰文 16-06-2021
公众评估报告 公众评估报告 荷兰文 18-11-2021
资料单张 资料单张 波兰文 16-06-2021
产品特点 产品特点 波兰文 16-06-2021
公众评估报告 公众评估报告 波兰文 18-11-2021
资料单张 资料单张 葡萄牙文 16-06-2021
产品特点 产品特点 葡萄牙文 16-06-2021
公众评估报告 公众评估报告 葡萄牙文 18-11-2021
资料单张 资料单张 罗马尼亚文 16-06-2021
产品特点 产品特点 罗马尼亚文 16-06-2021
公众评估报告 公众评估报告 罗马尼亚文 18-11-2021
资料单张 资料单张 斯洛伐克文 16-06-2021
产品特点 产品特点 斯洛伐克文 16-06-2021
公众评估报告 公众评估报告 斯洛伐克文 18-11-2021
资料单张 资料单张 斯洛文尼亚文 16-06-2021
产品特点 产品特点 斯洛文尼亚文 16-06-2021
公众评估报告 公众评估报告 斯洛文尼亚文 18-11-2021
资料单张 资料单张 芬兰文 16-06-2021
产品特点 产品特点 芬兰文 16-06-2021
公众评估报告 公众评估报告 芬兰文 18-11-2021
资料单张 资料单张 瑞典文 16-06-2021
产品特点 产品特点 瑞典文 16-06-2021
公众评估报告 公众评估报告 瑞典文 18-11-2021
资料单张 资料单张 挪威文 16-06-2021
产品特点 产品特点 挪威文 16-06-2021
资料单张 资料单张 冰岛文 16-06-2021
产品特点 产品特点 冰岛文 16-06-2021
资料单张 资料单张 克罗地亚文 16-06-2021
产品特点 产品特点 克罗地亚文 16-06-2021
公众评估报告 公众评估报告 克罗地亚文 18-11-2021

搜索与此产品相关的警报

查看文件历史